Compare Star Bulk Carriers Corp (SBLK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Star Bulk Carriers Corp trades at $27.66 (market cap $3.17B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 41.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SBLK | VRTX | |
|---|---|---|
Market Cap | $3.17B | $132.79B |
Sector | Industrials | Health |
52-Week High | $29.15 | $529.65 |
52-Week Low | $16.79 | $376.62 |
Enterprise Value | $3.65B | $126.92B |
Dividend Yield | 6.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $28.90, up 1.08% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.21 per share, and declared a $0.90 dividend. Fundamentals show robust profitability with a net income margin of 23.87% and a P/E ratio of 11.15, indicating potential value. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though the impact appears neutral.
The outlook for SBLK is positive, driven by strong earnings growth, healthy cash flow, and a favorable analyst consensus with 58.34% buy ratings. Key opportunities include high dividend yields and operational efficiency, while risks involve dry bulk rate volatility and competitive pressures in the shipping sector. Investors should weigh the company's solid financials against industry cyclicality.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
